Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is abrdn Life Sciences Investors FCF Yield %?
abrdn Life Sciences InvestorsHQL -2.47%51 FCF Yield % is 5.92 as of Aug. 20, 2026, which is 2% below its 10-year median of 6.04. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,507 Asset Management companies, abrdn Life Sciences Investors ranks better than 63.9% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
abrdn Life Sciences Investors FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
abrdn Life Sciences Investors FCF Yield % Related Terms
abrdn Life Sciences Investors FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, abrdn Life Sciences Investors's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors FCF Yield % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's FCF Yield % distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a FCF Yield % of 5.92 as of Aug. 20, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on abrdn Life Sciences Investors and its competitors. This is near median its historical median of 6.04. Over the past decade, abrdn Life Sciences Investors' FCF Yield % has ranged from 4.56 to 6.55. According to the industry distribution chart, abrdn Life Sciences Investors ranks #544 out of 1507 companies in the Asset Management industry, placing it in the top 36.1%.
Is abrdn Life Sciences Investors' FCF Yield % too high?
abrdn Life Sciences Investors' current FCF Yield % of 5.92 is near median its 10-year median of 6.04. Over the past 10 years, this metric has ranged from a low of 4.56 to a high of 6.55. The Asset Management industry median FCF Yield % is 1.96. abrdn Life Sciences Investors' value of 5.92 is 202% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #544 out of 1507 companies in the Asset Management industry, which is above the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' FCF Yield % compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #544 out of 1507 companies for FCF Yield %. This puts abrdn Life Sciences Investors in the upper half of its industry. The industry median FCF Yield % is 1.96. abrdn Life Sciences Investors' value of 5.92 is 202% above this benchmark. Historically, abrdn Life Sciences Investors' own FCF Yield % has ranged from 4.56 to 6.55 over the past decade. While the company's 10-year median is 6.04 vs. the industry median of 1.96, abrdn Life Sciences Investors has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for an Asset Management company?
The median FCF Yield % among Asset Management companies is 1.96, based on 1,507 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current FCF Yield % of 5.92 is 202% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median FCF Yield % is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current FCF Yield % is 5.92, which is near median its own 10-year median of 6.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current FCF Yield % is 5.92, which is near median its 10-year median of 6.04 and 202% above the Asset Management industry median of 1.96. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current FCF Yield % is 5.92 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
FCF Yield %: 5.92 (near median its 10-year median of 6.04)
GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
Industry Position: 202% above the Asset Management median (#544 of 1507)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
